Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
16 Apr 24
DEF 14A
Definitive proxy
16 Apr 24
S-3ASR
Automatic shelf registration
28 Feb 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
28 Feb 24
8-K
Regulation FD Disclosure
13 Dec 23
8-K
Regulation FD Disclosure
11 Dec 23
8-K
Departure of Directors or Certain Officers
22 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
3 Nov 23
8-K
Departure of Directors or Certain Officers
10 Oct 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
2 Aug 23
8-K
Editas Medicine Announces Offering of Common Stock
15 Jun 23
424B5
Prospectus supplement for primary offering
15 Jun 23
424B5
Prospectus supplement for primary offering
14 Jun 23
8-K
Regulation FD Disclosure
9 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
5 Jun 23
8-K
Departure of Directors or Certain Officers
17 May 23
10-Q
2023 Q1
Quarterly report
5 May 23
8-K
Editas Medicine Announces First Quarter 2023 Results and Business Updates
5 May 23
ARS
2022 FY
Annual report to shareholders
18 Apr 23
DEFA14A
Additional proxy soliciting materials
18 Apr 23
DEF 14A
Definitive proxy
18 Apr 23
8-K
Departure of Directors or Certain Officers
13 Apr 23
8-K
Departure of Directors or Certain Officers
14 Mar 23
S-8
Registration of securities for employees
22 Feb 23
10-K
2022 FY
Annual report
22 Feb 23
8-K
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
22 Feb 23
8-K
Departure of Directors or Certain Officers
9 Jan 23
8-K
Other Events
6 Dec 22
8-K
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
17 Nov 22
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
2 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Editas Medicine Announces Second Quarter 2022 Results and Business Updates
3 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 22
10-Q
2022 Q1
Quarterly report
4 May 22
8-K
Editas Medicine Announces First Quarter 2022 Results and Business Updates
4 May 22
Latest ownership filings
SC 13G/A
STATE STREET CORP
10 Apr 24
4
Erick Lucera
5 Mar 24
4
Linda Burkly
5 Mar 24
4
Gilmore Neil O'Neill
5 Mar 24
4
Baisong Mei
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
24 Jan 24
SC 13G/A
STATE STREET CORP
10 Jan 24
4
Bruce Eaton
7 Dec 23
4
Bruce Eaton
16 Nov 23
4
Bruce Eaton
9 Nov 23
4
Bruce Eaton
7 Sep 23
4
Bruce Eaton
15 Aug 23
4
Bruce Eaton
10 Aug 23
SC 13G
Deep Track Capital, LP
4 Aug 23
4
Linda Burkly
25 Jul 23
3
Linda Burkly
25 Jul 23
4
Baisong Mei
21 Jul 23
4
Gilmore Neil O'Neill
7 Jun 23
4
Bruce Eaton
7 Jun 23
4
Jessica Hopfield
5 Jun 23
4
Bernadette Connaughton
5 Jun 23
4
Emma Reeve
5 Jun 23
4
Akshay Vaishnaw
5 Jun 23
4
Andrew Hirsch
5 Jun 23
4
David Scadden
5 Jun 23
4
Meeta Chatterjee
5 Jun 23
144
Notice of proposed sale of securities
2 Jun 23
4
Erick Lucera
18 May 23
3
Erick Lucera
18 May 23
4
MICHELLE ROBERTSON
15 May 23
4
Bruce Eaton
15 May 23
144
Notice of proposed sale of securities
11 May 23
4
Bruce Eaton
11 May 23
4
Elliott M. Levy
13 Apr 23
3
Elliott M. Levy
13 Apr 23
4
MICHELLE ROBERTSON
6 Mar 23
4
Baisong Mei
6 Mar 23